AVGN Avigen (MM)

Audio Webcast Scheduled for 12:00 Noon (EDT) on Thursday, September 28, 2006 ALAMEDA, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Avigen, Inc. (NASDAQ:AVGN) a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today that President and Chief Executive Officer Kenneth Chahine, Ph.D., J.D., will present at the UBS Global Life Sciences Conference: o Thursday, September 28, 2006 - from 12:00-12:30 p.m. EDT in New York City at the Grand Hyatt New York Hotel. UBS will conduct a live audio webcast of the presentation. To access the webcast over the Internet, please go to http://www.avigen.com/ . Rebroadcast of the presentation will be available shortly after the conclusion of the session and can be accessed over the internet at http://www.avigen.com/ . About Avigen Avigen is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. Avigen's strategy is to complete the requirements of clinical development for each of the candidates in its product pipeline, and continue to look for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing, with the goal of becoming a fully integrated commercial biopharmaceutical company committed to its small molecule and biologics neurology products. The company is currently developing AV650 for spasticity and neuromuscular spasm and two candidates for neuropathic pain, AV411 and AV333. Additionally, the company is advancing toward clinical trials a novel therapy for the treatment of multiple bleeding disorders, including hemophilia A and B, AV513. For more information about Avigen, consult the company's website at http://www.avigen.com/ . Statement under the Private Securities Litigation Reform Act This press release contains forward-looking statements, which include, among others, statements relating to Avigen's intention of completing the requirements of clinical development for each of the candidates in its product pipeline; looking for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing; and becoming a fully integrated commercial biopharmaceutical company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the fact that development of small molecule therapeutics and other therapeutic discovery and development is a time- and resource-intensive process, which may result in the expenditure of a significant amount of time and resources with no marketable product resulting from the effort; and the risk that Avigen will not be able to obtain regulatory approvals for its drug products, which is required prior to marketing drug products. In addition, there are many other risks and uncertainties inherent in the development of drug products. Other risks and uncertainties relating to Avigen are detailed in reports filed by Avigen with the Securities and Exchange Commission, including Avigen's Quarterly Report on Form 10-Q for the period ended June 30, 2006, under the caption "Risks Related to our Business" in Item 2 of Part 1 of that report, which was filed with the SEC on August 4, 2006. DATASOURCE: Avigen, Inc. CONTACT: Michael Coffee, Chief Business Officer of Avigen, Inc., +1-510-748-7372, or Web site: http://www.avigen.com/

Copyright